Introduction {#Sec1}
============

Managing type 2 diabetes (T2D) is a challenging task due to the continual decline in beta-cell function that occurs. This progressive debilitating condition ultimately mandates the use of insulin in most, if not all patients \[[@CR1]\]. Timely initiation and active intensification of insulin is highly recommended to decrease the risk of long-term complications \[[@CR2]\]. The American Diabetes Association recommends a target glycated hemoglobin (HbA~1c~) level of \<7.0% as an established standard of good glycemic control \[[@CR3]\]. Despite these guidelines, it has been observed that initiation and intensification of insulin in routine clinical practice is often delayed over fears of hypoglycemia, weight gain and effects on patients' quality of life (QoL) \[[@CR1], [@CR4]\]. Other factors such as insulin availability, needle phobia and economic considerations are also possible barriers that can have a significant impact on patient adherence to treatment \[[@CR5]\].

Conventional basal insulins, such as neutral protamine Hagedorn (NPH) and insulin glargine have variable absorption kinetics resulting in increased within-patient blood glucose variability and an associated risk of hypoglycemia \[[@CR6], [@CR7]\]. Also, the weight gain associated with conventional insulin therapy may increase blood pressure and worsen lipid profiles \[[@CR8]\]. The development of long-acting basal insulin analogs, such as insulin detemir (IDet), with improved pharmacokinetics has been shown to have a positive effect on the balance between effective glycemic control and hypoglycemic risk \[[@CR9]\].

IDet is able to closely mimic endogenous insulin secretion and has a prolonged time-action profile due to its self-association and albumin-binding properties \[[@CR10]\]. It is prescribed once- or twice-daily as an adjunct to oral anti-diabetic drugs (OADs), glucagon-like peptide-1 analogs or as combination therapy with short- or rapid-acting insulins \[[@CR11]\]. Previously, it has been demonstrated that IDet therapy results in lower within-subject variability of fasting plasma glucose (FPG) when compared with NPH insulin therapy \[[@CR12]\]. Also, the effectiveness of glucose control with IDet has been observed with a reduced risk of hypoglycemia and no concerns about weight gain \[[@CR13], [@CR14]\].

The clinical benefits of insulin analogs, including IDet, could become an integral part of managing T2D, a disease that has reached epidemic proportions worldwide \[[@CR15]\]. Developing countries from the Near East region face a serious socioeconomic burden of increasing diabetes incidence. According to the International Diabetes Federation, in 2012, the prevalence of diabetes in Israel, Jordan, Lebanon and Pakistan was 7.85%, 11.62%, 17.04% and 7.89%, respectively \[[@CR15]\]. Additionally, Lebanon is listed among the top 10 countries for diabetes prevalence worldwide \[[@CR16]\]. Active measures to control and manage this disease are warranted. In order to increase awareness and provide appropriate guidance on T2D management the availability of local clinical data is essential. This 24-week observational study was thus conducted in T2D patients from four Near East Countries (Israel, Lebanon, Jordan and Pakistan) with an aim to evaluate the post-authorization experience with IDet in combination with OADs.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This multinational, prospective, observational study evaluated the safety and efficacy of 24 weeks of treatment with IDet (Levemir^®^, Novo Nordisk, Bagsvaerd, Denmark) in T2D patients from four Near East countries (Israel, Jordan, Lebanon and Pakistan) between April 2009 and August 2010. Patients prescribed IDet at the discretion of their consulting physicians, based on clinical judgement and country-specific Summary of Product Characteristics or Product Information reports, were enrolled in the study. Any subsequent changes in dose or frequency of administration of IDet or OADs were determined by the physician. IDet was commercially available and prescribed in accordance with local healthcare regulations. There were no predefined study procedures and all assessments were performed as part of routine clinical care. The physicians evaluated patients at baseline, the interim visit (approximately 12 weeks post-baseline visit) and final visit (approximately 24 weeks post-baseline visit).

Patients {#Sec4}
--------

This study included any T2D patient previously treated with one or more OADs (metformin, sulfonylureas, repaglinide, thiazolidinediones) or newly diagnosed T2D patients starting IDet ± OAD therapy. Patients currently being treated with IDet or any other insulin regimen, including bolus therapy, were excluded from the study. Also, patients with a reported hypersensitivity to IDet or any of its excipients were not included in this study. The study did not include women who were pregnant, breast feeding, had the intention of becoming pregnant within 6 months or those of childbearing potential and not using adequate contraceptive methods.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

Outcomes {#Sec5}
--------

The primary safety objective was to evaluate change in the number of hypoglycemicepisodes from the 4 weeks preceding the baseline visit compared with after 24 weeks of IDet treatment. Information on hypoglycemic episodes was collected based on patients' recall of the last 4 weeks before baseline and Week 24. Minor hypoglycemic events were described as symptoms of hypoglycemia with confirmation by plasma glucose measurement \<3.1 mmol/L (56 mg/dL) and which was handled by the patient himself/herself, or any asymptomatic plasma glucose level \<3.1 mmol/L (56 mg/dL). Nocturnal hypoglycemic events were defined as individualized symptomatic events consistent with hypoglycemia that occurred while the patient was asleep, between bedtime after the evening insulin injection and before getting up in the morning (if relevant, before morning determination of FPG and before morning injection). Severe central nervous system symptoms consistent with hypoglycemia in which the patient was unable to treat himself/herself, or reversal of symptoms after either glucagon or intravenous glucose administration were categorized as major hypoglycemic events. Additionally, hypoglycemia due to the fasting regimen, Ramadan, was also reported. The incidence of adverse drug reactions (ADRs) was reported as the secondary safety objective.

The primary efficacy endpoint was to determine the effects of IDet on glycemic control as reflected by changes in HbA~1c~ levels after 24 weeks of treatment. Secondary endpoints included evaluation of the number of patients achieving HbA~1c~ targets of \<7.0% and ≤6.5%; changes in FPG, post-breakfast post-prandial plasma glucose (PPPG) and body weight; and FPG variability from baseline to Week 24. FPG variability was defined as the standard deviation (SD) of the three most recent FPG values.

Statistical Analysis {#Sec6}
--------------------

Approximately 2,000 patients were considered sufficient to evaluate primarily the safety of IDet in this study. This sample size was estimated to provide a statistical power greater than 99% to detect a 1.0% change in HbA~1c~ from baseline based on a standard deviation of 1.2 and an estimated drop-out rate of 20%.

Patients who had received at least one dose of IDet and reported any post-baseline data were included in the full analysis set. Demographic characteristics, HbA~1c~, FPG, PPG and body weight were summarized using descriptive statistics. Categorical data were summarized using the number (*n*) and percentage. The paired *t* test was used to analyze the change from baseline to Week 24 in HbA~1c~, FPG, PPPG and body weight. The change in the proportion of patients with HbA~1c~ \<7.0% or ≤6.5% was evaluated using the Chi square test. All statistical analyses were based on two-sided tests and a significance level of *α* = 0.05. All data were analyzed using SAS Version 9.1.3 (SAS^®^ Institute Inc., Cary, North Carolina, USA).

Results {#Sec7}
=======

Patient Disposition {#Sec8}
-------------------

Of the 2,155 patients enrolled, 2,106 (97.7%) were exposed to the study drug. A total of 1,843 (85.5%) patients completed the study and 263 (12.2%) withdrew from the study. The reasons for premature discontinuation from the study included lost contact (146 patients, 6.8%), ADRs (6 patients, 0.3%) and other reasons (111 patients, 5.2%), which included non-compliance, consent withdrawal and therapy switch to OADs or other insulins. The demographic characteristics along with OAD use at baseline for the entire cohort and patients that withdrew are presented in Table [1](#Tab1){ref-type="table"}. Prior to study enrolment, biguanides (84.9%), sulfonylureas (78.0%) and thiazolidinediones (17.9%) were the most commonly administered OADs. The most common physician's reason to initiate IDet therapy was to improve glycemic control in 2,038 patients (96.8%), while the other common reasons were to reduce plasma glucose variability and to control unstable diabetes in 827 (39.3%) and 656 (31.1%) patients, respectively.Table 1Patient demographics and baseline characteristicsParametersEntire cohort^a^Withdrawals*n*2,106263Sex (%) Male55.151.7 Female44.948.3Age (years)^b^57.1 (11.0)57.1 (11.8)Body weight (kg)^b^80.2 (14.1)80.5 (13.6)BMI (kg/m^2^)^b^29.4 (5.1)29.7 (5.0)Diabetes duration (years)^b^9.2 (5.4)9.5 (5.8)HbA~1c~ (%)^b^9.6 (1.6)9.7 (1.8)OADs at baseline, *n* (%) Biguanides1,687 (80.1)263 (100.0) Sulfonylureas1,497 (71.1)155 (58.9) Thiazolidinediones292 (13.9)21 (8.0)*BMI* body mass index, *HbA* ~*1c*~ glycated hemoglobin A~1c~, *OAD* oral anti-diabetic drug, *SD* standard deviation^a^Patients had received at least one dose of IDet^b^Data are mean (SD)

Insulin Dose {#Sec9}
------------

Mean (±SD) IDet dose at baseline was 0.20 ± 0.09 U/kg (15.6 ± 7.1 U/day), titrated up to 0.34 ± 0.14 U/kg (27.1 ± 11.4 U/day) by Week 24.

Hypoglycemia {#Sec10}
------------

Overall, major, minor and nocturnal hypoglycemic events and hypoglycemic events due to the fasting regimen, Ramadan, are reported in Table [2](#Tab2){ref-type="table"}. The incidence of hypoglycemia (all events) appeared to increase slightly during the study, from 1.37 events/patient-year at Week 24 compared with 1.30 events/patient-year at baseline. The rate of major hypoglycemic episodes appeared to be lower at Week 24 (0.02 events/patient-year) in comparison with baseline (0.15 events/patient-year). The rate of nocturnal hypoglycemia appeared similar at baseline and Week 24 (0.40 and 0.39 events/patient-year, respectively). The rate of hypoglycemia due to fasting in Ramadan also appeared similar at baseline and Week 24 (0.07 and 0.06 events/patient-year, respectively).Table 2Baseline and 24-week event rates of hypoglycemiaHypoglycemic eventBaseline (events/patient-year)Week 24 (events/patient-year)Total All events1.301.37 Major0.150.02 Minor1.151.30 Nocturnal0.400.39 Due to fasting regimen^a^0.070.06Hypoglycemic episodes were collected based on patients' recall of the last 4 weeks before baseline and Week 24^a^Fasting regimen at Ramadan

Adverse Drug Reactions {#Sec11}
----------------------

A total of 9 ADRs were reported in 9 patients (0.4%) during the study. Of these, one event in one patient was a serious ADR of chronic renal failure. In all, 12 treatment emergent adverse events were reported in 11 patients (0.5%). Of the 6 ADRs that led to discontinuation of IDet, 5 events (3 drug hypersensitivity/drug allergy; 1 pruritus; 1 drug eruption) were considered probably related to IDet, while one event of bone pain was considered possibly related to IDet. These events were mild to moderate in intensity.

Body Weight {#Sec12}
-----------

Mean body weight did not change significantly from baseline (80.5 ± 13.8 kg) to Week 24 (80.4 ± 13.5 kg, *p* = 0.567).

Glucose Control {#Sec13}
---------------

Mean HbA~1c~ levels improved significantly from 9.6 ± 1.6% at baseline to 7.6 ± 1.1% at Week 24 (mean change, −2.0 ± 1.6%, *p* \< 0.0001) (Table [3](#Tab3){ref-type="table"}). HbA~1c~ \<7.0% was reported in 424 of 1,574 patients (26.9%) at Week 24 compared with 29 of 1,896 patients (1.5%) at baseline. HbA~1c~ ≤6.5% was achieved by 16 of 1,896 patients (0.8%) at baseline, increasing to 189 of 1,574 patients (12.0%) by Week 24.Table 3Baseline and 24-week data for glycemic parametersParameter*n*BaselineWeek 24Change*p* valueHbA~1c~ (%)1,4609.6 (1.6)7.6 (1.1)−2.0 (1.6)\<0.0001FPG (mg/dL)1,532201.5 (59.5)124.9 (31.6)−76.6 (62.5)\<0.0001FPG variability (mg/dL)44322.1 (18.6)12.0 (11.7)−10.1 (19.8)\<0.0001PPPG (mg/dL)940264.2 (65.7)167.2 (36.8)−97.1 (68.9)\<0.0001Data are mean (SD). FPG variability was defined as the SD of the three most recent FPG values*FPG* fasting plasma glucose, *HbA* ~*1c*~ glycated hemoglobin A~1c~, *PPPG* postprandial plasma glucose, *SD* standard deviation

At Week 24, there was a statistically significant mean decrease of 76.6 ± 62.5 mg/dL in FPG (*p* \< 0.0001, Table [3](#Tab3){ref-type="table"}). The decrease in FPG variability from baseline to Week 24 was statistically significant (−10.1 ± 19.8 mg/dL, *p* \< 0.0001) as was the reduction in post-breakfast PPPG levels (Week 24, 167.2 ± 36.8 mg/dL vs baseline, 264.2 ± 65.7 mg/dL, *p* \< 0.0001, Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec14}
==========

Previously, it has been established that adding basal insulin to existing OAD therapy is an effective treatment strategy to manage uncontrolled T2D \[[@CR17]\]. This study assessed the effects of IDet in combination with OADs in patients with T2D from Israel, Lebanon, Jordan and Pakistan. Introducing IDet therapy was well tolerated and resulted in marked improvements in glucose control after 24 weeks.

Baseline glycemic control in this cohort was poor. The average baseline HbA~1c~ level was 9.6%, while FPG and post-breakfast PPPG levels were 201.5 mg/dL and 264.2 mg/dL, respectively. This calls for an imperative need to design and implement more aggressive strategies to optimize T2D management in routine clinical practice in the Near East countries.

Initiating IDet significantly improved HbA~1c~, FPG and PPPG following 24 weeks of treatment. A total of 424 patients (26.9%) achieved the target HbA~1c~ level of \<7.0% with 189 patients (12.0%) achieving the more aggressive target of HbA~1c~ ≤6.5% after 24 weeks of treatment. Additionally, there were indications of a reduction in plasma glucose fluctuation as assessed by evaluating the standard deviations of the three most recent FPG levels. These improvements were seen alongside a low risk of hypoglycemia. As an expected outcome with first-time insulin initiation, there was a marginal increase in the rate of overall hypoglycemia from baseline to Week 24. However, the incidence of major hypoglycemia was lower at Week 24 compared with baseline. The incidence of major hypoglycemia could be reduced due to initial responses to a change in therapy. Also, this study included only insulin-naïve patients who have a much lower rate of hypoglycemia compared with prior insulin users \[[@CR18]\]. Nevertheless, we also acknowledge that a recall bias may have been introduced that could have masked the actual incidence of hypoglycemia. The clinical safety and efficacy of treatment was demonstrated without administering high doses of IDet (0.20 U/kg to 0.34 U/kg) throughout the study period. Although the actual IDet dose in this study was lower than that reported in interventional trials \[[@CR19], [@CR20]\], a significant change in glycemic control was observed. This positive response to therapy could also encourage physicians to resort to more active therapy intensification, leading to enhanced management of T2D.

Previously, it has been reported that every 2.5% decrease in HbA~1c~ is associated with a weight gain of \~5 kg \[[@CR21]\]. In contrast, average body weight remained fairly constant in our study despite a significant 2.0% decrease in mean HbA~1c~ level. Raslová et al. \[[@CR22]\] also demonstrated that patients on IDet experienced less weight gain than those on NPH insulin in a pooled analysis of 900 patients with T2D. Several theories have been proposed to justify the low weight gain observed with IDet therapy. The low glucose variability reported with IDet therapy may minimize defensive snacking resulting in decreased weight gain. Also, IDet may induce the satiety signaling mechanism in the central nervous system or suppress adipogenesis in the peripheral tissues due to its albumin-binding properties \[[@CR23]\]. IDet has a prolonged therapeutic action owing to its strong tendency to self-associate and remain highly bound to albumin in the subcutaneous depot \[[@CR24]\]. Nevertheless, the exact mechanism of action resulting in low weight gain following IDet therapy has yet to be elucidated.

The United Kingdom Prospective Diabetes study demonstrated that 53% of patients treated with sulfonylurea monotherapy required insulin over a period of 6 years \[[@CR25]\]. The gradual decline in beta-cell mass and function in patients with T2D is correlated with an increase in HbA~1c~ levels, even after the use of more than one OAD \[[@CR26]\]. Hence, insulin therapy becomes mandatory for all patients. However, intensification with insulin therapy also increases the risk of hypoglycemia. Our study demonstrates that initiating IDet therapy effectively enhances glycemic control, without increasing the risk of hypoglycemia and weight gain, in line with the data from randomized controlled trials \[[@CR19], [@CR27]\].

The observational design of the current study has limitations such as the lack of a control arm, retrospective data collection methods, non-standardization of reported data and possible recall bias for the incidence of hypoglycemia. However, the results obtained are useful for evaluating a treatment in real-life setting rather than in randomized controlled trials in which the data are often influenced by the restricted sample of patients enrolled. Also, observational studies are considered to be more useful in evaluating the post-authorization safety profile of drugs compared with randomized controlled trials \[[@CR28]\]. This study included patients on OAD therapy alone and newly diagnosed patients starting IDet + OAD therapy, irrespective of their concomitant medical conditions or other baseline criteria, thus representing situations that community-based practitioners encounter. The data evaluated in this study may thus be useful in guiding the optimization of T2D management in routine practice.

Conclusion {#Sec15}
==========

In summary, the results of this observational study in the Near East region countries showed that treatment initiation with a long-acting basal analog, IDet, in combination with OAD therapy, can be a safe and effective treatment strategy for T2D patients.
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